Stoke Therapeutics (STOK) Other Accumulated Expenses (2018 - 2026)

Stoke Therapeutics has reported Other Accumulated Expenses for 9 years, with the latest figure at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 27.68% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (down 27.68% YoY), and the FY2025 full-year result was $1.1 million, up 40.77% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $1.5 million, up from $1.1 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $2.1 million in Q1 2025, with the low at $426000.0 in Q3 2022.
• Average Other Accumulated Expenses over 5 years is $899529.4, with a median of $753000.0 recorded in 2024.
• Year-over-year, Other Accumulated Expenses soared 4900.0% in 2022 and dropped 27.68% in 2026.
• Tracing STOK's Other Accumulated Expenses over 5 years: stood at $509000.0 in 2022, then jumped by 68.37% to $857000.0 in 2023, then declined by 12.14% to $753000.0 in 2024, then soared by 40.77% to $1.1 million in 2025, then soared by 41.51% to $1.5 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.5 million (Q1 2026), $1.1 million (Q4 2025), and $795000.0 (Q3 2025), per Business Quant data.

Peer Comparison